9 reports

  • 8.2 LACK OF SAFE AND EFFICACIOUS TREATMENT ALTERNATIVES
  • 6.3 TREATMENT GUIDELINES AND LEADING PRESCRIBED DRUGS

COHORT ONE RECEIVED TREATMENTS AT BASELINE AND DAY ##.

  • Hospital
  • Medical Biotechnology
  • Therapy
  • AbbVie Inc.
  • Remicade group
  • SWITCHING TREATMENT TO BIOSIMILAR IFX BY IBD PATIENT TYPE (NEXT 12 MONTHS)
  • SWITCHING TREATMENT TO BIOSIMILAR IFX BY IBD PATIENT TYPE (NEXT 12 MONTHS) - OVERALL, (N=100)

PREFERRED TREATMENT BY UC PATIENT TYPE - ##EU (N=##) Prescribing habits Ranked scores (##-##) Ranked ##st = ## points Ranked ##nd = ## points Ranked ##rd = ## point Charts display mean ranked score Patients with highly, active progressive disease Patients with extraintestinal manif

  • Biosimilar
  • Medical Biotechnology
  • Therapy
  • United States
  • Remicade group
  • 6.1 OVERVIEW
  • SWOT ANALYSIS, HUMIRA 2016

COHORT ONE RECEIVED TREATMENTS AT BASELINE AND DAY ##.

  • Autoimmune Disease
  • Epidemiology
  • Monoclonal Antibody
  • Therapy
  • Remicade group
  • RA TREATMENT COUNTRY PROFILE - SPAIN
  • RA TREATMENT COUNTRY PROFILE - FRANCE

ARTHRITIS RESEARCH & THERAPY; ##: ##-##.

  • Biosimilar
  • Epidemiology
  • Hospital
  • Therapy
  • Remicade group

TABLE OF CONTENTS (##/ ##) ##.

  • Biosimilar
  • Therapy
  • Market Size
  • Supply
  • Remicade group
  • AVERAGE ANNUAL TREATMENT COST OF HUMIRA, ENBREL, AND REMICADE 2014 ($)
  • Market challenges

They can be further classified into cyclooxygenase-## (COX-##) and COX-## inhibitors.

  • Pharmaceutical
  • Therapy
  • Amgen Inc.
  • Pfizer Inc.
  • Remicade group
  • GRAPPA TREATMENT GUIDELINES FOR PSA, 2015
  • COUNTRY PROFILE - JAPAN

Pharmacology & Therapeutics; ##(##): ##-##. & Therapy; ##(suppl ##): S##.

  • Biosimilar
  • Epidemiology
  • Therapy
  • East Asia
  • Remicade group
  • 5 Current Treatment Options
  • LEADING TREATMENTS FOR VASCULITIS, 2015

ARTHRITIS RESEARCH & THERAPY; ##(SUPPL ##): S##.

  • Autoimmune Disease
  • Epidemiology
  • Monoclonal Antibody
  • Therapy
  • Remicade group
  • JANSSEN (JOHNSON & JOHNSON) - 1/3
  • 1. ORIGINATOR ANTI-TNF ANTIBODIES

Treatment with MI## demonstrated significant in vivo antitumor activity in mice bearing JIMT-## xenografts.

  • Biosimilar
  • Pharmaceutical
  • Therapy
  • Remicade group
  • Roche Group